Journal
TUBERCULOSIS
Volume 88, Issue -, Pages S3-S17Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/S1472-9792(08)70032-5
Keywords
tuberculosis; Mycobacterium tuberculosis; drug discovery; fluoroquinolones; oxazolidinones; diarylquinolines; nitroimidazooxazoles; nitroimidazooxazines
Categories
Ask authors/readers for more resources
Drug discovery and development, from an initial disease treatment concept to a new drug application (NDA), is a complex, lengthy and expensive process. In this review we discuss the key stages of drug discovery and early development, including target identification and validation, assay development and screening, confirmed hits to leads, lead optimization, and progressing development candidates to an investigational new drug (IND) filing. We also provide particular examples of how this process is beginning to assist in the development of small molecule treatments for tuberculosis, by summarizing the status of the clinical development of several newer classes of drugs. These include the fluoroquinolones, oxazolidinones, diarylquinolines, and nitroimidazooxazoles and -oxazines. (c) 2008 Elsevier Ltd. All rights reserved
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available